Systems and methods for processing images to determine biomarker levels

US12579645B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12579645-B2
Application numberUS-202318451507-A
CountryUS
Kind codeB2
Filing dateAug 17, 2023
Priority dateAug 18, 2022
Publication dateMar 17, 2026
Grant dateMar 17, 2026

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Systems and methods are described herein for processing electronic medical images to predict a biomarker's presence, including receiving one or more digital medical images, the one or more digital medical images being of at least one pathology specimen associated with a patient. A machine learning system may determine a biomarker expression level prediction for the one or more digital medical images. The biomarker expression level prediction may be based on a determined transcriptomic score and protein expression score for the one or more digital medical images. A slide overlay indicating a region of tissue on the one or more digital medical images that is most likely to contribute to the slide level biomarker expression prediction may be generated.

First claim

Opening claim text (preview).

What is claimed is: 1 . A computer-implemented method for processing electronic medical images to predict a biomarker's presence, comprising: receiving one or more digital medical images, the one or more digital medical images being of at least one pathology specimen associated with a patient; determining a protein expression score for the one or more digital medical images, the protein expression score including an immunohistochemistry (IHC) score for each of the one or more digital medical images; determining a transcriptomic score including a level of Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2) mRNA; determining, by a machine learning system, a biomarker expression level prediction for the one or more digital medical images, the biomarker expression level prediction being based on the transcriptomic score and the protein expression score for the one or more digital medical images, wherein the biomarker expression level prediction is determined to be a true absence of human epidermal growth factor receptor 2 (HER2) expression upon determining that the immunohistochemistry score is IHC-0+, indeterminate, or equivocal-IHC-1+ and that the ERBB2 mRNA level is less than a predetermined value; and generating a slide overlay indicating a region of tissue on the one or more digital medical images that contributes to the biomarker expression level prediction. 2 . The method of claim 1 , further comprising: determining, salient regions of the received one or more digital medical images prior to determining the biomarker expression level, wherein non-salient image regions are excluded from subsequent processing. 3 . The method of claim 2 , wherein the one or more salient regions correspond to cancerous tissue. 4 . The method of claim 1 , wherein the one or more digital medical images are images of breast tissue stained with hematoxylin and eosin. 5 . The method of claim 1 , wherein the biomarker expression is human epidermal growth factor receptor 2. 6 . The method of claim 1 , wherein the biomarker expression level prediction is performed upon determining that the received one or more slides has a immunohistochemistry (IHC) score of IHC-0 or IHC-1. 7 . The method of claim 1 , wherein the predetermined value of ERBB2 mRNA is 7.6. 8 . The method of claim 1 , wherein generating a slide overlay includes generating a tissue map overlay and/or a heatmap overlay. 9 . A system for processing electronic medical images, the system comprising: at least one memory storing instructions; and at least one processor configured to execute the instructions to perform operations comprising: receiving one or more digital medical images, the one or more digital medical images being of at least one pathology specimen associated with a patient; determining a protein expression score for the one or more digital medical images, the protein expression score including an immunohistochemistry (IHC) score for each of the one or more digital medical images; determining a transcriptomic score including a level of Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2) mRNA; determining, by a machine learning system, a biomarker expression level prediction for the one or more digital medical images, the biomarker expression level prediction being based on the transcriptomic score and the protein expression score for the one or more digital medical images, wherein the biomarker expression level prediction is determined to be a true absence of human epidermal growth factor receptor 2 (HER2) expression upon determining that the immunohistochemistry score is IHC-0+, indeterminate, or equivocal-IHC-1+ and that the ERBB2 mRNA level is less than a predetermined value; and generating a slide overlay indicating a region of tissue on the one or more digital medical images that contributes to the biomarker expression level prediction. 10 . The system of claim 9 , further comprising: determining, salient regions of the received one or more digital medical images prior to determining the biomarker expression level, wherein non-salient image regions are excluded from subsequent processing. 11 . The system of claim 10 , wherein the one or more salient regions correspond to cancerous tissue. 12 . The system of claim 9 , wherein the biomarker expression level prediction is performed upon determining that the received one or more slides has a immunohistochemistry (IHC) score of IHC-0 or IHC-1. 13 . The system of claim 9 , wherein the one or more digital medical images are images of breast tissue stained with hematoxylin and eosin. 14 . The system of claim 9 , wherein the predetermined value is predetermined value of ERBB2 mRNA is 7.6. 15 . A non-transitory computer-readable medium storing instructions that, when executed by a processor, perform operations processing electronic medical images, the operations comprising: receiving one or more digital medical images, the one or more digital medical images being of at least one pathology specimen associated with a patient; determining a protein expression score for the one or more digital medical images, the protein expression score including an immunohistochemistry (IHC) score for each of the one or more digital medical images; determining a transcriptomic including a level of Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2) mRNA; determining, by a machine learning system, a biomarker expression level prediction for the one or more digital medical images, the biomarker expression level prediction being based on the transcriptomic score and the protein expression score for the one or more digital medical images, wherein the biomarker expression level prediction is determined to be a true absence of human epidermal growth factor receptor 2 (HER2) expression upon determining that the immunohistochemistry score is IHC-0+, indeterminate, or equivocal-IHC-1+ and that the ERBB2 mRNA level is less than a predetermined value; and generating a slide overlay indicating a region of tissue on the one or more digital medical images that contributes to the biomarker expression level prediction. 16 . The non-transitory computer-readable medium of claim 15 , further comprising: determining, salient regions of the received one or more digital medical images prior to determining the biomarker expression level, wherein non-salient image regions are excluded from subsequent processing. 17 . The non-transitory computer-readable medium of claim 16 , wherein the one or more salient regions correspond to cancerous tissue. 18 . The non-transitory computer-readable medium of claim 15 , wherein the one or more digital medical images are images of breast tissue stained with hematoxylin and eosin. 19 . The non-transitory computer-readable medium of claim 15 , wherein the predetermined value of ERBB2 mRNA is 7.6.

Assignees

Inventors

Classifications

  • Mammography; Breast · CPC title

  • Cell structures in vitro; Tissue sections in vitro · CPC title

  • Image fusion; Image merging · CPC title

  • using two or more images, e.g. averaging or subtraction · CPC title

  • Salient features, e.g. scale invariant feature transforms [SIFT] · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12579645B2 cover?
Systems and methods are described herein for processing electronic medical images to predict a biomarker's presence, including receiving one or more digital medical images, the one or more digital medical images being of at least one pathology specimen associated with a patient. A machine learning system may determine a biomarker expression level prediction for the one or more digital medical i…
Who is the assignee on this patent?
Paige Ai Inc
What technology area does this patent fall under?
Primary CPC classification G06T7/0012. Mapped technology areas include Physics.
When was this patent published?
Publication date Tue Mar 17 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).